04:17 AM EDT, 08/08/2025 (MT Newswires) -- PTC Therapeutics ( PTCT ) reported a Q2 loss late Thursday of $0.83 per diluted share, narrower than a loss of $1.29 a year earlier.

Analysts polled by FactSet expected $1.02 loss.

Revenue for the quarter that ended June 30 was $178.9 million, down from $186.7 million a year earlier.

Analysts surveyed by FactSet expected $172.3 million.

The company expects full-year 2025 revenue to be between $650 million and $800 million, which includes products and royalties.